Neoplasms

All Conditions

Heart and Blood Diseases

Digestive System Diseases

Carcinoma

Hypertension

Carcinoma, Hepatocellular

Hypertension, Portal

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

PLAT

wu dong, MD

qu shuping, doctor

The aim of this study is to compare the operative complication and short-/long-term therapeutic effects of percutaneous local ablative therapy (PLAT) versus surgical resection(SR) on small hepatocellular carcinoma(HCC) patients with clinically significant portal hypertension(CSPH) so as to lend clinical and theoretical basis of the therapeutic schemes for the disease.

HCC is a major health problem worldwide, with an estimated incidence ranging between 500,000 and 1,000,000 new cases annually. It is the fifth most common cancer in the world and the third most common cause of cancer-related death,especially in East-Asia countries.SR remains the first therapeutic option for a cure but is suitable only for 9%-27% of patients.The presence of significant background cirrhosis often precludes liver resection for HCC.Even though these HCC patients undergo SR，the incidence of posthepatectomy liver failure(PHLF) and death would be high，especially to HCC patients complicating CSPH，whose corresponding risk of PHLF and persistent PHLF were 59.02%and 14.75%respectively in our past study. It is extremely urgent to search a safe and effective means in this subgroup of HCC patients.PLAT, a recently developed local ablative technique, has attracted the greatest interest and popularity because of its effectiveness and safety,with a 3-year survival rate of 62-77%,a low treatment complication rate of 8-9% and a low treatment mortality rate of 0-0.5%.However, there is still debate on whether PLAT or SR is the most suitable therapy for HCC.To our knowledge,there have been no study on the therapy of HCC complicating CSPH.

Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma

A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria

Eastern Hepatobiliary Surgery Hospital

vice president of the Eastern Hepatobiliary Surgery Hospital

Symptoms and General Pathology

Nervous System Diseases

Pain, Postoperative

Pain

Postoperative Complications

Neurologic Manifestations

Channel Blockers

Analgesics

Anticonvulsants

Central Nervous System Depressants

Psychotropic Drugs

All Drugs and Chemicals

Hematinics

Bone Density Conservation Agents

Pregabalin

Liver Extracts

Calcium

Calcium Channel Blockers

Calcium, Dietary

Hormones

Anti-Anxiety Agents

Single, 150 mg pre-operative oral dose of Pregabalin

One 150 mg oral dose of Pregabalin given before surgery

One oral dose of placebo given before surgery

Placebo (for Pregabalin)

li ai jun, MD

Pregabalin 150mg or placebo are administered 1 hour preoperatively in patients undergoing partial hepatectomy. Postoperatively, patients receive morphine as rescue analgesic. Morphine consumption in the first 48 hours is documented. Postoperative pain is measured by the visual analogue scale (VAS) score.

Methods: In this Randomized Controlled Trial, patients undergoing partial hepatectomy will be administered a single pre-operative dose of Pregabalin or a placebo. Primary endpoints are as follows:

* Post-operative analgesic requirements
* Post-operative VAS scale (rated 0-10)
* Complications
* Post-operative antiemetic requirement
* Length of stay

Preoperative Pain Control in Liver Surgery Patients

A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 150 mg Will Improve Pain Control in Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma	NCT01860222	Hepatocellular ...	SR PLAT	18 Years - 70 Years	Eastern Hepatobiliary Surgery Hospital
Preoperative Pain Control in Liver Surgery Patients	NCT01923948	Pain, Postopera... Hepatocellular ...	Pregabalin Placebo (for Pr...	18 Years - 70 Years	Eastern Hepatobiliary Surgery Hospital
Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma	NCT01860222	Hepatocellular ...	SR PLAT	18 Years - 70 Years	Eastern Hepatobiliary Surgery Hospital

Spots Global Cancer Trial Database for randomized controlled trials(rcts)